1
|
Yeung A, Aziz A, Taji L, Cooper R, Oliver MJ, Blake PG, McFarlane P. Infection Control Practices in In-Center Hemodialysis Units During Wave 1 of the COVID-19 Pandemic in Ontario, Canada: Research Letter. Can J Kidney Health Dis 2023; 10:20543581221146033. [PMID: 36654932 PMCID: PMC9841452 DOI: 10.1177/20543581221146033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Accepted: 11/17/2022] [Indexed: 01/15/2023] Open
Abstract
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that caused coronavirus disease 2019 (COVID-19), the multisystem disease central to the COVID-19 pandemic. As patients receiving in-center maintenance hemodialysis require treatment 3 times weekly, they were unable to fully isolate. It was important for in-center hemodialysis units to implement robust infection control practices to ensure patient safety and minimize risk of transmitting SARS-CoV-2 among patients and staff. There are 27 renal programs within Ontario, Canada, providing care for about 9000 people across about 100 in-center hemodialysis units. These units are funded by the Ontario Renal Network (ORN), which is part of the provincial agency Ontario Health. Objective The objective was to track infection control practices that were implemented by in-center hemodialysis units and be able to provide a descriptive narrative of the COVID-19 pandemic response of Ontario's hemodialysis units between March and September 2020. Methods Between May and September 2020, data were collected from Ontario's 27 renal programs on the implementation of key infection control practices, including symptom screening, use of personal protective equipment, testing, practices specifically related to patients from congregate living settings, other prevention practices, and outbreak management. There were 4 data collection cycles, each approximately 1 month apart. The results were compiled and shared across the province, and infection control practices were also discussed at provincial COVID-19 teleconferences hosted by the ORN. Results By March 2020, all but one renal program had implemented one or more forms of symptom screening, all renal programs had implemented physical distancing in waiting rooms and restricted visitors, and 74% of renal programs had implemented universal masking for all staff. By April 2020, 89% of renal programs had implemented universal masking for all patients, 52% had implemented enhanced contact and droplet precautions for suspected or positive cases, and 59% of renal programs tested all patients from congregate living settings regularly (with a low symptom threshold for testing). Infection control practices became more homogeneous across renal programs over time, and most practices were in place as of the last data collection. Conclusions The renal system in Ontario was able to respond quickly within the first 2 months of the pandemic to minimize the spread of COVID-19 within in-center hemodialysis units. Through provincial teleconferences, infection control practices were shared across the province as the pandemic and hemodialysis unit responses evolved. This supported renal programs to advocate locally if their hospital was lagging in practices felt to be of value in other hemodialysis units. Although no direct correlation can be made regarding the implementation of infection control practices within in-center hemodialysis units and the number of COVID-19 cases in this population, the limited number of outbreaks in hemodialysis units may have been influenced by the proactive response of renal programs. Practices described in this article may support management and response to subsequent waves of COVID-19 or future similar infectious diseases.
Collapse
Affiliation(s)
- Angie Yeung
- Ontario Renal Network, Ontario Health, Toronto, Canada
| | - Anas Aziz
- Ontario Renal Network, Ontario Health, Toronto, Canada
| | - Leena Taji
- Ontario Renal Network, Ontario Health, Toronto, Canada
| | | | - Matthew J. Oliver
- Ontario Renal Network, Ontario Health, Toronto, Canada,Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Peter G. Blake
- Ontario Renal Network, Ontario Health, Toronto, Canada,London Health Sciences Centre, ON, Canada
| | - Phil McFarlane
- Ontario Renal Network, Ontario Health, Toronto, Canada,St. Michael’s Hospital, Toronto, ON, Canada,Phil McFarlane, Division of Nephrology, St. Michael’s Hospital, 61 Queen Street East, 9th Floor, Toronto, ON M5C 2T2 Canada.
| |
Collapse
|
2
|
Roushani J, Thomas D, Oliver MJ, Ip J, Tang Y, Yeung A, Taji L, Cooper R, Magner PO, Garg AX, Blake PG. Acute kidney injury requiring renal replacement therapy in people with COVID-19 disease in Ontario, Canada: a prospective analysis of risk factors and outcomes. Clin Kidney J 2021; 15:507-516. [PMID: 35198157 PMCID: PMC8690186 DOI: 10.1093/ckj/sfab237] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Indexed: 12/11/2022] Open
Abstract
ABSTRACT
Background
Severely ill people with coronavirus disease 2019 (COVID-19) are at risk of acute kidney injury treated with renal replacement therapy (AKI-RRT). The understanding of the risk factors and outcomes for AKI-RRT is incomplete.
Methods
We prospectively collected data on the incidence, demographics, area of residence, time course, outcomes and associated risk factors for all COVID-19 AKI-RRT cases during the first two waves of the pandemic in Ontario, Canada.
Results
There were 271 people with AKI-RRT, representing 0.1% of all diagnosed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases. These included 10% of SARS-CoV-2 admissions to intensive care units (ICU). Median age was 65 years, with 11% <50 years, 76% were male, 47% non-White and 48% had diabetes. Overall, 59% resided in the quintile of Ontario neighborhoods with the greatest ethnocultural composition and 51% in the two lowest income quintile neighborhoods. Mortality was 58% at 30 days after RRT initiation, and 64% at 90 days. By 90 days, 20% of survivors remained RRT-dependent and 31% were still hospitalized. On multivariable analysis, people aged >70 years had higher mortality (odds ratio 2.4, 95% confidence interval 1.3, 4.6). Cases from the second versus the first COVID-19 wave were older, had more baseline comorbidity and were more likely to initiate RRT >2 weeks after SARS-CoV-2 diagnosis (34% versus 14%; P < 0.001).
Conclusions
AKI-RRT is common in COVID-19 ICU admissions. Residency in areas with high ethnocultural composition and lower socioeconomic status are strong risk factors. Late-onset AKI-RRT was more common in the second wave. Mortality is high and 90-day survivors have persisting high morbidity.
Collapse
Affiliation(s)
- Jian Roushani
- Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
| | - Doneal Thomas
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Matthew J Oliver
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
- Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Jane Ip
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Yiwen Tang
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Angie Yeung
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Leena Taji
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Rebecca Cooper
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Peter O Magner
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
- Division of Nephrology, University of Ottawa, Ottawa, ON, Canada
| | - Amit X Garg
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
- Division of Nephrology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
| | - Peter G Blake
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
- Division of Nephrology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
| |
Collapse
|
3
|
Sniekers DC, Jung JKH, Blake PG, Cooper R, Leis JA, Muller MP, Padure V, Holm P, Yeung A, Taji L, McFarlane P, Oliver MJ. Province-Wide Prevalence Testing for SARS-CoV-2 of In-Center Hemodialysis Patients and Staff in Ontario, Canada: A Cross-Sectional Study. Can J Kidney Health Dis 2021; 8:20543581211036213. [PMID: 34394945 PMCID: PMC8358577 DOI: 10.1177/20543581211036213] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 07/09/2021] [Indexed: 01/12/2023] Open
Abstract
Background: People receiving in-center hemodialysis face a high risk for contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experience poor outcomes. During the first wave of the coronavirus disease 2019 (COVID-19) pandemic in Ontario (between March and June 2020), it was unclear whether asymptomatic or presymptomatic cases were common and whether widespread testing of all dialysis patients and staff would identify cases earlier and prevent transmission. Ontario has a population of about 14.5 million. Approximately 8900 people receive dialysis across 102 in-center dialysis units. Objective: The objective of this study was to determine participation rates for patients and staff in point prevalence testing in dialysis units across the province and to determine the prevalence of asymptomatic or presymptomatic infection. Design: Cross-sectional study design. Setting: In-center hemodialysis units at 27 renal programs across Ontario. Participants: Patients and staff in in-center dialysis units in Ontario. Measurements: Participation rates, demographic data, SARS-CoV-2 positivity rates, and COVID-19-related symptom data. Methods: From June 8 to 30, 2020, all in-center dialysis patients and staff in the Province of Ontario were requested to undergo a symptom screening assessment and nasopharyngeal swab. Testing was done using polymerase chain reaction to detect SARS-CoV-2. A standardized questionnaire of atypical and typical COVID-19-related symptoms was administered to patients, to assess for new or worsening COVID-19-related symptoms. Results: Patient participation was 83% (7155 of 8612) of which 15 tests were positive: less than 5 (<0.07%) were new positive cases, 7 were false positive, and the remaining were recovered positives. Half of the new positive cases had symptoms. Common symptoms reported included fatigue (4%), falls (4%), runny nose (3%), dyspnea (3%), and cough (3%). Staff participation was 49% (2109 of 4325), and less than 5 (<0.24%) were asymptomatic positive. Limitations: As point prevalence testing was voluntary, not all patients and staff participated. Lower participation rate may be due to decreasing new cases in Ontario, and testing or pandemic fatigue, among other factors. This study did not use serology to identify prior infections because it was not widely available in Ontario. With respect to the standardized symptom questionnaire, it was only available in English and French and could not be tested due to the urgency of the initiative. Conclusions: Participation among patients in point prevalence testing was good, but participation among staff was relatively low. Asymptomatic positivity in the dialysis patient and staff population was rare during the first wave of the COVID-19 pandemic in Ontario.
Collapse
Affiliation(s)
| | - James K H Jung
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Peter G Blake
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada.,Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
| | - Rebecca Cooper
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Jerome A Leis
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | | | | | - Philip Holm
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Angie Yeung
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Leena Taji
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Phil McFarlane
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada.,St Michael's Hospital, Toronto, ON, Canada
| | - Matthew J Oliver
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada.,Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| |
Collapse
|
4
|
Blake PG, McCormick BB, Taji L, Jung JK, Ip J, Gingras J, Boll P, McFarlane P, Pierratos A, Aziz A, Yeung A, Patel M, Cooper R. Growing home dialysis: The Ontario Renal Network Home Dialysis Initiative 2012-2019. Perit Dial Int 2021; 41:441-452. [PMID: 33969759 DOI: 10.1177/08968608211012805] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The Ontario Renal Network (ORN), a provincial government agency in Ontario, Canada, launched an initiative in 2012 to increase home dialysis use province-wide. The initiative included a new modality-based funding formula, a standard mandatory informatics system, targets for prevalent home dialysis rates, the development of a 'network' of renal programmes with commitment to home dialysis and a culture of accountability with frequent meetings between ORN and each renal programme leadership to review their results. It also included funding of home dialysis coordinators, encouragement and funding of assisted peritoneal dialysis (PD), and support for catheter insertion and urgent start PD. Between 2012 and 2017, home dialysis use rose from 21.9% to 26.5% and then between 2017 and 2019 stabilised at 26% to 26.5%. Over 7 years, the absolute number of people on home dialysis increased 40% from 2222 to 3105, while the number on facility haemodialysis grew 11% from 7935 to 8767. PD prevalence rose from 16.6% to 20.9%, a relative increase of 25%. The initiative showed that a sustained multifaceted approach can increase home dialysis utilisation.
Collapse
Affiliation(s)
- Peter G Blake
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada.,Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada.,10033London Health Sciences Centre, Ontario, Canada
| | - Brendan B McCormick
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada.,Division of Nephrology, Department of Medicine, 27337The Ottawa Hospital, Ontario, Canada
| | - Leena Taji
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada
| | - James Kh Jung
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada
| | - Jane Ip
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada
| | - Joanie Gingras
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada
| | - Phil Boll
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada.,Trillium Health Partners, Mississauga, Ontario, Canada
| | - Phil McFarlane
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada.,Division of Nephrology, Department of Medicine, University of Toronto, Ontario, Canada.,St Michaels Hospital, Toronto, Ontario, Canada
| | | | - Anas Aziz
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada
| | - Angie Yeung
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada
| | - Monisha Patel
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada
| | - Rebecca Cooper
- Ontario Renal Network, 573450Ontario Health, Toronto, Ontario, Canada
| |
Collapse
|
5
|
Taji L, Thomas D, Oliver MJ, Ip J, Tang Y, Yeung A, Cooper R, House AA, McFarlane P, Blake PG. COVID-19 chez les patients ontariens sous dialyse à long terme. CMAJ 2021; 193:E655-E662. [PMID: 33941528 PMCID: PMC8112626 DOI: 10.1503/cmaj.202601-f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/18/2021] [Indexed: 11/16/2022] Open
Abstract
CONTEXTE: Les patients sous dialyse à long terme pourraient avoir un risque accru d’infection par le coronavirus du syndrome respiratoire aigu sévère 2 (SRAS-CoV-2), et de maladie et de mortalité associées. Nous avons voulu décrire l’incidence, les facteurs de risque et les issues de l’infection chez ces patients en Ontario (Canada). MÉTHODES: Nous avons utilisé des ensembles de données reliées pour comparer les caractéristiques de la maladie et la mortalité chez les patients sous dialyse à long terme en Ontario qui ont testé positif pour le SRAS-CoV-2 et ceux qui n’ont pas développé d’infection, entre le 12 mars et le 20 août 2020. Nous avons recueilli des données sur l’infection par le SRAS-CoV-2 de manière prospective. Nous avons évalué les facteurs de risque d’infection et de mortalité par des analyses de régression logistique multivariées. RÉSULTATS: Pendant la période à l’étude, 187 patients dialysés sur 12 501 (1,5 %) ont reçu un diagnostic d’infection par le SRAS-CoV-2. Parmi eux, 117 (62,6 %) ont été hospitalisés, et le taux de mortalité était de 28,3 %. Les facteurs prédictifs significatifs associés à l’infection incluaient l’hémodialyse dans un centre plutôt que la dialyse à domicile (rapport de cotes [RC] 2,54; intervalle de confiance [IC] à 95 % 1,59–4,05), le fait de vivre dans un établissement de soins de longue durée (RC 7,67; IC à 95 % 5,30–11,11), le fait d’habiter la région du Grand Toronto (RC 3,27; IC à 95 % 2,21–4,80), les ethnicités Noire (RC 3,05; IC à 95 % 1,95–4,77), du sous-continent indien (RC 1,70; IC à 95 % 1,02–2,81) et autres non blanches (RC 2,03; IC à 95 % 1,38–2,97) et les quintiles de revenu inférieurs (RC 1,82; IC à 95 % 1,15–2,89). INTERPRÉTATION: Les patients sous dialyse à long terme sont exposés à un risque accru d’infection par le SRAS-CoV-2 et de mortalité due à la maladie à coronavirus 2019. Il faudra travailler à éliminer les facteurs de risque d’infection et vacciner ces patients en priorité.
Collapse
Affiliation(s)
- Leena Taji
- Réseau rénal de l'Ontario (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Santé Ontario; Département de médecine (Oliver), Université de Toronto, Toronto, Ont.; Faculté de médecine et de dentisterie Schulich (House, Blake), Université Western, London, Ont.; Hôpital St. Michael's (McFarlane), Toronto, Ont
| | - Doneal Thomas
- Réseau rénal de l'Ontario (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Santé Ontario; Département de médecine (Oliver), Université de Toronto, Toronto, Ont.; Faculté de médecine et de dentisterie Schulich (House, Blake), Université Western, London, Ont.; Hôpital St. Michael's (McFarlane), Toronto, Ont
| | - Matthew J Oliver
- Réseau rénal de l'Ontario (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Santé Ontario; Département de médecine (Oliver), Université de Toronto, Toronto, Ont.; Faculté de médecine et de dentisterie Schulich (House, Blake), Université Western, London, Ont.; Hôpital St. Michael's (McFarlane), Toronto, Ont
| | - Jane Ip
- Réseau rénal de l'Ontario (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Santé Ontario; Département de médecine (Oliver), Université de Toronto, Toronto, Ont.; Faculté de médecine et de dentisterie Schulich (House, Blake), Université Western, London, Ont.; Hôpital St. Michael's (McFarlane), Toronto, Ont
| | - Yiwen Tang
- Réseau rénal de l'Ontario (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Santé Ontario; Département de médecine (Oliver), Université de Toronto, Toronto, Ont.; Faculté de médecine et de dentisterie Schulich (House, Blake), Université Western, London, Ont.; Hôpital St. Michael's (McFarlane), Toronto, Ont
| | - Angie Yeung
- Réseau rénal de l'Ontario (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Santé Ontario; Département de médecine (Oliver), Université de Toronto, Toronto, Ont.; Faculté de médecine et de dentisterie Schulich (House, Blake), Université Western, London, Ont.; Hôpital St. Michael's (McFarlane), Toronto, Ont
| | - Rebecca Cooper
- Réseau rénal de l'Ontario (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Santé Ontario; Département de médecine (Oliver), Université de Toronto, Toronto, Ont.; Faculté de médecine et de dentisterie Schulich (House, Blake), Université Western, London, Ont.; Hôpital St. Michael's (McFarlane), Toronto, Ont
| | - Andrew A House
- Réseau rénal de l'Ontario (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Santé Ontario; Département de médecine (Oliver), Université de Toronto, Toronto, Ont.; Faculté de médecine et de dentisterie Schulich (House, Blake), Université Western, London, Ont.; Hôpital St. Michael's (McFarlane), Toronto, Ont
| | - Phil McFarlane
- Réseau rénal de l'Ontario (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Santé Ontario; Département de médecine (Oliver), Université de Toronto, Toronto, Ont.; Faculté de médecine et de dentisterie Schulich (House, Blake), Université Western, London, Ont.; Hôpital St. Michael's (McFarlane), Toronto, Ont
| | - Peter G Blake
- Réseau rénal de l'Ontario (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Santé Ontario; Département de médecine (Oliver), Université de Toronto, Toronto, Ont.; Faculté de médecine et de dentisterie Schulich (House, Blake), Université Western, London, Ont.; Hôpital St. Michael's (McFarlane), Toronto, Ont.
| |
Collapse
|
6
|
Taji L, Thomas D, Oliver MJ, Ip J, Tang Y, Yeung A, Cooper R, House AA, McFarlane P, Blake PG. COVID-19 in patients undergoing long-term dialysis in Ontario. CMAJ 2021; 193:E278-E284. [PMID: 33542093 PMCID: PMC8034346 DOI: 10.1503/cmaj.202601] [Citation(s) in RCA: 58] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Accepted: 01/18/2021] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Patients undergoing long-term dialysis may be at higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and of associated disease and mortality. We aimed to describe the incidence, risk factors and outcomes for infection in these patients in Ontario, Canada. METHODS We used linked data sets to compare disease characteristics and mortality between patients receiving long-term dialysis in Ontario who were diagnosed SARS-CoV-2 positive and those who did not acquire SARS-CoV-2 infection, between Mar. 12 and Aug. 20, 2020. We collected data on SARS-CoV-2 infection prospectively. We evaluated risk factors for infection and death using multivariable logistic regression analyses. RESULTS During the study period, 187 (1.5%) of 12 501 patients undergoing dialysis were diagnosed with SARS-CoV-2 infection. Of those with SARS-CoV-2 infection, 117 (62.6%) were admitted to hospital and the case fatality rate was 28.3%. Significant predictors of infection included in-centre hemodialysis versus home dialysis (odds ratio [OR] 2.54, 95% confidence interval [CI] 1.59-4.05), living in a long-term care residence (OR 7.67, 95% CI 5.30-11.11), living in the Greater Toronto Area (OR 3.27, 95% CI 2.21-4.80), Black ethnicity (OR 3.05, 95% CI 1.95-4.77), Indian subcontinent ethnicity (OR 1.70, 95% CI 1.02-2.81), other non-White ethnicities (OR 2.03, 95% CI 1.38-2.97) and lower income quintiles (OR 1.82, 95% CI 1.15-2.89). INTERPRETATION Patients undergoing long-term dialysis are at increased risk of SARS-CoV-2 infection and death from coronavirus disease 2019. Special attention should be paid to addressing risk factors for infection, and these patients should be prioritized for vaccination.
Collapse
Affiliation(s)
- Leena Taji
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael's Hospital (McFarlane), Toronto, Ont
| | - Doneal Thomas
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael's Hospital (McFarlane), Toronto, Ont
| | - Matthew J Oliver
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael's Hospital (McFarlane), Toronto, Ont
| | - Jane Ip
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael's Hospital (McFarlane), Toronto, Ont
| | - Yiwen Tang
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael's Hospital (McFarlane), Toronto, Ont
| | - Angie Yeung
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael's Hospital (McFarlane), Toronto, Ont
| | - Rebecca Cooper
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael's Hospital (McFarlane), Toronto, Ont
| | - Andrew A House
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael's Hospital (McFarlane), Toronto, Ont
| | - Phil McFarlane
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael's Hospital (McFarlane), Toronto, Ont
| | - Peter G Blake
- Ontario Renal Network (Taji, Thomas, Oliver, Ip, Tang, Yeung, Cooper, McFarlane, Blake), Ontario Health; Department of Medicine (Oliver), University of Toronto, Toronto, Ont.; Schulich School of Medicine and Dentistry (House, Blake), Western University, London, Ont.; St. Michael's Hospital (McFarlane), Toronto, Ont.
| |
Collapse
|
7
|
Taji L, Battistella M, Grill AK, Cunningham J, Hemmelgarn BL, Quinn KM, Thomas A, Brimble KS. Medications Used Routinely in Primary Care to be Dose-Adjusted or Avoided in People With Chronic Kidney Disease: Results of a Modified Delphi Study. Ann Pharmacother 2020; 54:625-632. [DOI: 10.1177/1060028019897371] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background: Chronic kidney disease (CKD) affects up to 18% of those over the age of 65 years. Potentially inappropriate medication prescribing in people with CKD is common. Objectives: Develop a pragmatic list of medications used in primary care that required dose adjustment or avoidance in people with CKD, using a modified Delphi panel approach, followed by a consensus workshop. Methods: We conducted a comprehensive literature search to identify potential medications. A group of 17 experts participated in a 3-round modified Delphi panel to identify medications for inclusion. A subsequent consensus workshop of 8 experts reviewed this list to prioritize medications for the development of point-of-care knowledge translation materials for primary care. Results: After a comprehensive literature review, 59 medications were included for consideration by the Delphi panel, with a further 10 medications added after the initial round. On completion of the 3 Delphi rounds, 66 unique medications remained, 63 requiring dose adjustment and 16 medications requiring avoidance in one or more estimated glomerular filtration rate categories. The consensus workshop prioritized this list further to 24 medications that must be dose-adjusted or avoided, including baclofen, metformin, and digoxin, as well as the newer SGLT2 inhibitor agents. Conclusion and Relevance: We have developed a concise list of 24 medications commonly used in primary care that should be dose-adjusted or avoided in people with CKD to reduce harm. This list incorporates new and frequently prescribed medications and will inform an updated, easy to access source for primary care providers.
Collapse
Affiliation(s)
- Leena Taji
- Ontario Renal Network, Cancer Care Ontario, Toronto, Ontario, Canada
| | - Marisa Battistella
- University of Toronto and University Health Network, Toronto, Ontario, Canada
| | - Allan K. Grill
- University of Toronto and University Health Network, Toronto, Ontario, Canada
| | - Jessie Cunningham
- Ontario Renal Network, Cancer Care Ontario, Toronto, Ontario, Canada
| | | | | | - Ann Thomas
- Ontario Renal Network, Cancer Care Ontario, Toronto, Ontario, Canada
| | - K. Scott Brimble
- Ontario Renal Network, Cancer Care Ontario, Toronto, Ontario, Canada
- McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
8
|
Tucci MC, Dvorkin-Gheva A, Johnson E, Cheon P, Taji L, Agarwal A, Foster J, Szechtman H. Performance of compulsive behavior in rats is not a unitary phenomenon - validation of separate functional components in compulsive checking behavior. Eur J Neurosci 2014; 40:2971-9. [PMID: 24935528 PMCID: PMC4215607 DOI: 10.1111/ejn.12652] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2014] [Revised: 05/06/2014] [Accepted: 05/08/2014] [Indexed: 11/29/2022]
Abstract
A previous analysis of the quinpirole sensitisation rat model of obsessive-compulsive disorder revealed that the behavioral phenotype of compulsive checking consists of three constitutive components – vigor of checking performance, focus on the task of checking, and satiety following a bout of checking. As confirmation of this analysis, the aim of the present study was to reconstitute, without quinpirole treatment, each of the putative components, with the expectation that these would self-assemble into compulsive checking. To reconstitute vigor and satiety, the employed treatment was a bilateral lesion of the nucleus accumbens core (NAc), as this treatment was shown previously to exaggerate these components. To reconstitute focus, the employed treatment was a low dose of the serotonin-1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin hydrochloride (DPAT) (0.0625 mg/kg), as high doses of this drug induce compulsive behavior and exacerbate focus. Results showed that injection of DPAT to NAc lesion rats did yield compulsive checking. Neither the drug alone nor the NAc lesion by itself produced compulsive checking. The demonstrated synthesis of compulsive checking by the combined treatment of low-dose DPAT and NAc lesion strengthened the previous fractionation of the model obsessive-compulsive disorder phenotype into three constitutive components, and suggested a role for serotonin-1A receptors outside the NAc in enhanced focus on the task of checking.
Collapse
Affiliation(s)
- Mark C Tucci
- Department of Psychiatry and Behavioural Neurosciences, Health Science Centre, McMaster University, Room 4N82, 1280 Main Street West, Hamilton, ON, Canada, L8S 4K1
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Tucci MC, Dvorkin-Gheva A, Graham D, Amodeo S, Cheon P, Kirk A, Peel J, Taji L, Szechtman H. Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD). Psychopharmacology (Berl) 2013; 227:277-85. [PMID: 23354534 DOI: 10.1007/s00213-013-2976-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2012] [Accepted: 12/16/2012] [Indexed: 02/07/2023]
Abstract
RATIONALE The serotonergic agonist, meta-chlorophenylpiperazine (mCPP), produces inconsistent effects on obsessive-compulsive disorder (OCD) symptoms, perhaps because clinical studies have not utilized a homogenous OCD subgroup of patients. OBJECTIVES This study aimed to evaluate mCPP effects on functional components of compulsive checking, using the quinpirole sensitization rat model of OCD. METHODS In study 1, the effects of mCPP were evaluated in quinpirole rats with compulsive checking. Two experimental groups were co-injected with quinpirole (0.125 mg/kg) and mCPP (0.625 or 1.25 mg/kg), while one control group was co-injected with quinpirole (0.125 mg/kg) and saline and the other control group received co-injections of saline. In study 2, mCPP (0, 0.3125, 0.625, and 1.25 mg/kg) was administered repeatedly to naïve rats and induction of compulsive checking evaluated. RESULTS mCPP significantly attenuated quinpirole-induced compulsive checking behavior by reducing vigor of checking (indexed by frequency of checking and length of check) and increasing rest after a bout of checking (indexed by time to the next checking bout), but it did not affect focus on the task of checking (indexed by recurrence time of checking and number of stops before returning to check). In naïve rats, mCPP did not induce compulsive behavior, but the highest dose reduced vigor of checking performance compared to saline controls. CONCLUSIONS mCPP did not exacerbate or induce compulsive checking behavior. Instead, it ameliorated compulsive checking by reducing vigor of checking and increasing post-checking satiety, without affecting focus on checking. Ameliorative effects of mCPP may involve 5HT2A/2C receptors in substantia nigra pars reticulata that inhibit expression of motor vigor.
Collapse
Affiliation(s)
- Mark C Tucci
- Department of Psychiatry and Behavioural Neurosciences, Faculty of Health Sciences, McMaster University, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|